Product pipeline

Our medicines and vaccines in development are classified into three stages: phase I, phase II and phase III. These studies into the safety and efficacy of investigational products provide data to support applications to regulators for approval.

This page provides an outline of the medicines and vaccines in development.

Owing to the nature of drug development, many compounds - especially those in early stages of investigation - may be terminated through the development process. For competitive reasons, new projects in pre-clinical development are not disclosed and some project types may not be identified.

Brand names are trademarks either owned by and/or licensed to GSK or associated companies.

The content of our development pipeline will change over time as new compounds progress from discovery to development and from development to the market.

This annual pipeline information was updated in March 2018.

Key

Key

In-licence or other alliance relationship with third party
^
ViiV Healthcare, a global specialist HIV company with GSK, Pfizer, Inc. and Shionogi Limited as shareholders, is responsible for developing and delivering HIV medicines.
*
Also being developed for indications in another therapeutic area
1
Option-based alliance with Ionis Pharmaceuticals
2
Option-based alliance with Adaptimmune Ltd.
3
Option-based alliance with OncoMed Pharmaceuticals
4
Option-based alliance with Telethon and Ospedale San Raffaele
5
Option-based alliance with Valneva
S
Month of first submission
BLA
Biological Licence Application
MAA
Marketing Authorisation Application (Europe)
NDA
New Drug Application (US)
Phase I
Evaluation of clinical pharmacology, usually conducted in volunteers
Phase II
Determination of dose and initial evaluation of efficacy, conducted in a small number of patients
Phase III
Large comparative study (compound versus placebo and/or established treatment) in patients to establish clinical benefit and safety

MAA and NDA/BLA regulatory review milestones shown in the table below are those that have been achieved. Future filing dates are not included in this list.

Compound Type Indication Phase MAA NDA/BLA
HIV^ and Infectious Diseases scroll or swipe to view full table

dolutegravir + rilpivirine+

HIV integrase inhibitor + non-nucleoside reverse transcriptase inhibitor (NNRTI) HIV infections – two drug maintenance regimen Approved S: May17 A: Nov17

tafenoquine+

8-aminoquinoline plasmodium vivax malaria Submitted S: Nov17

Dectova (zanamivir) i.v.†

neuraminidase inhibitor (i.v.) influenza Submitted S: Nov17

dolutegravir + lamivudine

HIV integrase strand transfer inhibitor + nucleoside reverse transcriptase inhibitor (NRTI) HIV infection III

fostemsavir

HIV attachment inhibitor HIV infection III

cabotegravir

HIV integrase strand transfer inhibitor (long-acting) HIV pre-exposure prophylaxis III

cabotegravir +
rilpivirine†

HIV integrase strand transfer inhibitor + nonnucleoside reverse transcriptase inhibitor (NNRTI) (long-acting regimen) HIV infection III

gepotidacin (2140944)

type 2 topoisomerase inhibitor bacterial infections II

32288361

HBV antisense oligonucleotide hepatitis B II

33894041

HBV LICA antisense oligonucleotide hepatitis B II

CCI15106†

viral replication inhibitor (nucleoside) viral exacerbations of COPD I

3640254

HIV maturation inhibitor HIV infection I

3036656†

leucyl t-RNA synthetase inhibitor tuberculosis I
Respiratory scroll or swipe to view full table

mepolizumab

interleukin 5 (IL5) monoclonal antibody eosinophilic granulomatosis with polyangiitis Approved A:Dec17

Trelegy (fluticasone
furoate + vilanterol†
+ umeclidinium)

glucocorticoid agonist + long-acting beta2 agonist + muscarinic acetylcholine antagonist chronic obstructive pulmonary disease (COPD) Approved A:Nov17 A:Sep17

mepolizumab

interleukin 5 (IL5) monoclonal antibody COPD Submitted S:Nov17

fluticasone furoate +
vilanterol† +
umeclidinium

glucocorticoid agonist + long-acting beta2 agonist + muscarinic acetylcholine antagonist asthma III

mepolizumab

interleukin 5 (IL5) monoclonal antibody hypereosinophilic syndrome III

mepolizumab

interleukin 5 (IL5) monoclonal antibody nasal polyposis III

nemiralisib

phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor COPD (acute and chronic) II

danirixin

chemokine (C-X-C Motif) receptor 2 (CXCR2) antagonist (oral) COPD II

2586881†

recombinant human angiotensin converting enzyme 2 (rhACE2) acute lung injury II

2862277

tumour necrosis factor receptor-1 (TNFR1) domain antibody acute lung injury II

2245035

toll-like receptor 7 (TLR7) agonist asthma II

nemiralisib

phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor activated PI3K delta syndrome II

3772847†

interleukin 33r (IL33r) monoclonal antibody severe asthma II

2586881†

recombinant human angiotensin converting enzyme 2 (rhACE2) pulmonary arterial hypertension I

3008348

alpha V beta 6 integrin antagonist idiopathic pulmonary fibrosis I

nemiralisib

phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor bronchiectasis I

2292767

phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor COPD I

3511294

interleukin 5 (IL5) long-acting monoclonal antibody asthma I
Oncology scroll or swipe to view full table

3377794†

NY-ESO-1 autologous engineered TCR-T cells (engineered TCR) sarcoma, multiple myeloma, non-small cell lung cancer, melanoma and ovarian cancer II

2857916†

B-cell maturation antigen antibody drug conjugate multiple myeloma II

525762

BET family bromodomain inhibitor solid tumours and haematological malignancies I

3174998†

OX40 agonist monoclonal antibody solid tumours and haematological malignancies I

3326595

protein arginine methyltransferase 5 (PRMT5) inhibitor cancer I

3359609

induced T-cell costimulator (ICOS) agonist antibody cancer I

1795091

toll-like receptor 4 (TLR4) agonist cancer I

2636771

phosphatidylinositol 3-kinase (PI3K) beta inhibitor castration resistant prostate cancer I
Immuno-inflammation scroll or swipe to view full table

Benlysta

B lymphocyte stimulator monoclonal antibody (s.c.) systemic lupus erythematosus Approved A: Nov17 A: Jul17

3196165†

granulocyte macrophage colonystimulating factor monoclonal antibody osteoarthritis II

3196165†

granulocyte macrophage colonystimulating factor monoclonal antibody rheumatoid arthritis II

Benlysta + Rituxan

B lymphocyte stimulator monoclonal antibody (s.c.) + cluster of differentiation 20 (CD20) monoclonal antibody (i.v.) Sjogren's syndrome II

2982772

receptor-interacting protein 1 (RIP1) kinase inhibitor psoriasis II

2982772

receptor-interacting protein 1 (RIP1) kinase inhibitor rheumatoid arthritis II

2330811

oncostatin M (OSM) monoclonal antibody systemic sclerosis II

2982772

receptor-interacting protein 1 (RIP1) kinase inhibitor ulcerative colitis II

2831781†

lymphocyte activation gene 3 (LAG3) protein monoclonal antibody autoimmune disease I

2983559

receptor-interacting protein 2 (RIP2) kinase inhibitor inflammatory bowel diseases I

3335065

Kynurenine 3-monooxygenase inhibitor acute pancreatitis I
Future pipeline optionality scroll or swipe to view full table

daprodustat (1278863)

prolyl hydroxylase inhibitor (oral) anaemia associated with chronic renal disease III

dezamizumab
(2398852)† +
2315698†

serum amyloid P component (SAP) monoclonal antibody + SAP depleter (CPHPC) amyloidosis II

oxytocin (inhaled)†

oxytocin postpartum hemorrhage II

tapinarof (2894512)†

non-steroidal anti-inflammatory (topical) atopic dermatitis II

tapinarof (2894512)†

non-steroidal anti-inflammatory (topical) psoriasis II

2881078

selective androgen receptor modulator muscle wasting I
Vaccines scroll or swipe to view full table

Shingrix†
(Zoster Vaccine)

recombinant Herpes Zoster prophylaxis Approved (US) Submitted (EU) S: Nov16 A: Oct17

Rotavirus

live attenuated, PCV (Porcine circovirus) free Rotavirus prophylaxis III

MMR

live attenuated measles, mumps, rubella prophylaxis III (US) N/A

Ebola†

recombinant viral vector Ebola haemorrhagic fever prophylaxis II

S. pneumoniae next
generation†

recombinant – conjugated Streptococcus pneumoniae disease prophylaxis II

COPD

recombinant reduction of the frequency of moderate and severe acute exacerbations in COPD patients by targeting non-typeable Haemophilus influenzae and Moraxella catarrhalis II

Hepatitis C†

heterologous recombinant viral vectors hepatitis C virus prophylaxis: prevention of establishment of chronic infection II

Malaria next generation†

recombinant malaria prophylaxis (Plasmodium falciparum) II

Men ABCWY

recombinant – conjugated meningococcal A,B,C,W and Y disease prophylaxis in adolescents II

Shigella†

conjugated and outer membrane Shigella diarrhea prophylaxis II

Tuberculosis†

recombinant tuberculosis prophylaxis II

RSV

replication-defective recombinant viral vector respiratory syncytial virus prophylaxis in paediatric population II

Flu universal†

universal inactivated influenza vaccine Flu infection prophylaxis with broad protection over multiple seasons I/II

HIV†

recombinant proteins HIV infection prophylaxis II

There are no results for your selection.

Back to top